9-month 2024 Key Financial Figures 21.2% increase in adjusted EBITDA from continuing operations
Paiania, 14 November 2024 - Lavipharm S.A. reports key consolidated financial figures of the first nine months of 2024. An increase of 21.2% was posted on the Group’s adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) from continuing operations for the first nine months of...
14 November, 2024